Retrospective clinical analysis of circulating tumor DNA (ctDNA)–based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response in phase 3 trial of bintrafusp alfa vs. pembrolizumab treatment of non-small cell lung cancer (NSCLC).

Authors

Zheng Feng

Clinical Measurements Sciences, Global Research & Development, EMD Serono, Billerica, MA USA, an affiliate of Merck KGaA, Billerica, MA

Zheng Feng , Andreas Machl , Danyi Wang , Brooke Overstreet , Arielle Yablonovitch , Juergen Scheuenpflug

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

STAR-121: A phase 3, randomized study of domvanalimab (DOM) and zimberelimab (ZIM) in combination with chemotherapy vs pembrolizumab (pembro) and chemotherapy in patients with untreated metastatic non-small cell lung cancer (mNSCLC) with no actionable gene alterations.

First Author: Delvys Rodriguez-Abreu

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study.

First Author: Kersti Oselin

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.

First Author: Christos Chouaid

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.

First Author: Marina Chiara Garassino